TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-orientated training
Description: Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-orientated training
Description: Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-orientated training
Description: Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electrical nerve stimulation
Description: A identical-looking TENS devices that electrical circuit has been disconnected.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electrical nerve stimulation
Description: A identical-looking TENS devices that electrical circuit has been disconnected.
Study: NCT03863548

Intervention type: OTHER
Intervention: complication
Description: collection of post-operative bleeding complications

Intervention type: OTHER
Intervention: complication
Description: collection of post-operative bleeding complications
Study: NCT00763841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Stimulation will be given daily at a particular site for three days a week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT03516461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
Study: NCT03222128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Implantation of the SAPIEN 3
Study: NCT00174369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: 15 mg BID
Study: NCT03034824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP+940±15 nm diode laser
Description: In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP+Er,Cr:YSGG laser
Description: In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)-Control
Description: Only Non-surgical periodontal treatment
Study: NCT04629287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPCXM18
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
Study: NCT03105024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
Study: NCT00456235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophénolate Mofétil
Study: NCT04629287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KPCXM18
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
Study: NCT00193921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV, 25mg/m2, days 1, 8, 22

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose Radiotherapy
Description: External beam radiation, 40 Gy/20#/5 per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 200mg (flat dose) IV days 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2, IV, weekly
Study: NCT00456235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophénolate Mofétil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporine A
Study: NCT00193921

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Radiotherapy
Description: External beam radiation, 30 Gy/15#/5 per week
Study: NCT03559647

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Study: NCT02450162

Intervention type: PROCEDURE
Intervention: lateral rectus recession (bilateral)
Description: Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
Study: NCT00456235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporine A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT02504567

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser ablation
Description: Pulmonary vein isolation using the laser ablation catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: RF ablation
Description: Pulmonary vein isolation using the RF ablation catheter
Study: NCT00733044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Care
Description: The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
Study: NCT04193475

Intervention type: OTHER
Intervention: Analysis
Description: No intervention planned. Novel analysis of echocardiographic data.
Study: NCT01269697

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: 2 capsules 2 times per day during 6 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nutrof total
Description: 2 capsules 2 times per day during 6 month
Study: NCT03411473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN1884 in combination with pembrolizumab
Description: AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
Study: NCT02093598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT04568590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
Study: NCT03220217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 5-20μg
Description: Positron emission tomography (PET) imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 5-20μg
Description: Positron emission tomography (PET) imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 5-20μg
Description: Positron emission tomography (PET) imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 30-45μg
Description: Positron emission tomography (PET) imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 30-45μg
Description: Positron emission tomography (PET) imaging agent
Study: NCT00456235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study: NCT01581333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial treatment discontinuation
Description: Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard empirical antimicrobial treatment discontinuation
Description: The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3.
Study: NCT03527329

Intervention type: DEVICE
Intervention: WarmTouch Model 5900, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
Study: NCT02700386

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvant Hypofractionated Radiation
Description: Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
Study: NCT03914326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo tablets to be taken with water at the same time every morning in a fasting state
Study: NCT01617265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Procedure to Prevent Oversedation
Description: Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual sedation practice
Description: Sedation and analgesia will be administered according to the usual practices in each participating center.
Study: NCT02441517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
Study: NCT01880996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-chi/Qi-gong
Description: Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
Study: NCT00224952

Intervention type: OTHER
Intervention: No intervention; Urine Collection
Description: Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
Study: NCT03571568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg orally as per SmPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg orally as per SmPC
Study: NCT04746170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
Study: NCT01452919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04085757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long interval dinoprostone
Description: A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short interval dinoprostone
Description: A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Study: NCT02915003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health website
Description: e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
Study: NCT01743820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Study: NCT03220217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 30-45μg
Description: Positron emission tomography (PET) imaging agent
Study: NCT01755923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg once per day until the progression disease or intolerant side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
Study: NCT00670449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod was supplied in capsules.
Study: NCT04408716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Index Guided High-Power Short-Duration Strategy
Description: Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiofrequency Ablation Technique
Description: Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
Study: NCT03230240

Intervention type: DRUG
Intervention: HIPEC
Description: heated intraIP chemotherapy
Study: NCT01446835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens with print
Description: Investigational spherical contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A contact lens with print
Description: Commercially marketed (Singapore) spherical contact lens
Study: NCT00468013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Building Exercises
Description: Weekly exercises for 6 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Journaling
Description: Weekly exercises for 6 weeks
Study: NCT03679572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted partial nephrectomy super-selective clamping
Description: The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted partial nephrectomy with renal artery clamping
Description: Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
Study: NCT00800085

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: glucose 20%
Description: maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
Study: NCT01967927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MISO
Description: A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
Study: NCT01488227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000 IU of Vitamin D daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acts as a control for the Vitamin D intervention
Study: NCT02698020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room-air
Description: Provision of room-air
Study: NCT04256642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: A nerve block that injects local anesthetic in the Erector Spinae Plane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine at the time of spinal anesthesia